ALKERMES | ALKS - Ebitda


ALKERMES reported $120.06M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
ALKERMES USD 120.06M 19.15M Sep/2026
Amgen USD 5.8B 1.25B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 9.46B 3.54B Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
J&J USD 8.99B 721M Jun/2026
Malin Corporation EUR -1.1M 200K Dec/2024
Merck USD 1.42B 2.97B Jun/2026
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Otsuka Holdings JPY 174.82B 14.19B Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026